Skip to main content

Dicerna Licenses Gene Silencing IP from Plant Bioscience Limited

Premium

Dicerna Pharmaceuticals announced this week that it has taken a non-exclusive license to RNAi intellectual property held by Plant Bioscience Limited.

The IP includes US patent No. 8,097,710, as well as three related patents, which broadly cover the use of small RNAs to trigger post-transcriptional gene silencing and are based on the pioneering plant work of Sainsbury Laboratory researchers David Baulcombe and Andrew Hamilton.

In early 2012, a PBL official told Gene Silencing News that the organization aims to make the IP as widely available as possible.

Under the deal with PBL, Dicerna will have the rights to use the patented technology for human therapeutics. Financial terms of the arrangement were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.